EULAR/美国风湿病学会关于关节痛风险期类风湿关节炎发生的风险分层标准
EULAR/ACR联合专家委员会基于10个关节痛队列(含临床可疑关节痛和自身抗体阳性关节痛)的2293例有症状风险个体数据,开发了用于预测1年内进展为临床明显炎症性关节炎的风险分层标准。该标准由6个临床和血清学变量组成,AUC为0.80(95%CI 0.77-0.83);加入MRI检测的亚临床炎症变量后AUC为0.87(95%CI 0.82-0.90),对1年内按2010 EULAR/ACR标准发生RA的AUC为0.93(95%CI 0.90-0.97)。
要点
- EULAR/ACR风险分层标准由6个临床和血清学变量组成,用于关节痛风险人群1年内炎症性关节炎发生的分层。
- 6变量标准预测炎症性关节炎的AUC为0.80(95%CI 0.77-0.83),加入超声变量未提高区分能力。
- 加入MRI检测的亚临床炎症变量后AUC为0.87(95%CI 0.82-0.90),对RA发生的AUC为0.93(95%CI 0.90-0.97)。
核心结论
- EULAR/ACR风险分层标准已针对二级医疗中就诊的、被认为有RA风险的关节痛人群开发,可在无影像或有影像数据时应用,旨在为未来预防试验定义同质风险组。
研究设计与样本
- EULAR/ACR联合专家委员会基于10个关节痛队列(包括临床可疑关节痛和自身抗体阳性关节痛)的风险因素和结局数据开展研究,共纳入2293例有症状的风险个体。
主要发现
- 由晨僵、患者报告的关节肿胀、握拳困难、C反应蛋白、类风湿因子和抗环瓜氨酸肽抗体6个临床和血清学变量组成的分层方法,预测炎症性关节炎发生的AUC为0.80(95%CI 0.77-0.83)。
- 纳入超声变量未提高区分能力。
- 纳入MRI检测的亚临床炎症变量后,AUC为0.87(95%CI 0.82-0.90)。
- 在同时具有临床、血清学和MRI变量时,敏感性和特异性均>75%。
- 对于RA发生,含MRI的标准AUC为0.93(95%CI 0.90-0.97)。
关键数值与推荐
- 风险分层标准由6个临床和血清学变量(晨僵、患者报告的关节肿胀、握拳困难、C反应蛋白、类风湿因子、抗环瓜氨酸肽抗体)组成。
- 6变量标准预测1年内炎症性关节炎发生的AUC为0.80(95%CI 0.77-0.83)。
- 加入MRI亚临床炎症变量后预测炎症性关节炎发生的AUC为0.87(95%CI 0.82-0.90),预测RA发生的AUC为0.93(95%CI 0.90-0.97)。
- 在具有临床、血清学和MRI变量时,敏感性和特异性均>75%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The field of rheumatoid arthritis (RA) is moving towards identification of and intervention in people at risk of RA, but a validated risk stratification method is lacking. This work was undertaken to develop a risk stratification method for persons presenting with arthralgia considered to be at risk of RA. METHODS: A joint EULAR/American College of Rheumatology (ACR) expert committee was established. Risk factor and outcome data from 10 arthralgia cohorts (including clinically suspect arthralgia and autoantibody-positive arthralgia) were studied. The work focused on differentiating the risk of progression to clinically apparent inflammatory arthritis (IA) within 1 year, using clinical and serologic variables, without and with subclinical joint inflammation detected by ultrasound (US) or magnetic resonance imaging (MRI). Developing RA according to the 2010 EULAR/ACR criteria within 1 year was a secondary outcome. A set of validated risk stratification criteria was developed. RESULTS: Using data from 2,293 symptomatic at-risk individuals, a stratification method was derived consisting of 6 clinical and serologic variables (morning stiffness, patient-reported joint swelling, difficulty making a fist, C-reactive protein, rheumatoid factor, and anti-citrullinated peptide antibody) yielding an area under the curve (AUC) of 0.80 (95% confidence interval [CI] 0.77-0.83) for IA development. The inclusion of US variables did not increase the discriminative ability. When MRI-detected subclinical inflammation variables were included, the AUC was 0.87 (95% CI 0.82-0.90). In the presence of clinical, serologic, and MRI variables, a sensitivity and specificity of >75% was achieved. For RA development, the AUC of the criteria with MRI was 0.93 (95% CI 0.90-0.97). CONCLUSIONS: EULAR/ACR risk stratification criteria have been developed for people with arthralgia in secondary care who are considered at risk for RA. The criteria can be applied in the absence or presence of imaging data and have been developed to define homogeneous risk groups for future prevention trials.
引用
- van Steenbergen HW, Doornkamp F, Alivernini S, et al. EULAR/American College of Rheumatology Risk Stratification Criteria for Development of Rheumatoid Arthritis in the Risk Stage of Arthralgia. Arthritis Rheumatol. 2025. PMID: 40343380. doi:10.1002/art.43218
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。